Studies of rare genetic diseases have frequently opened doors to an understanding of fundamental cellular mechanisms. Two articles in the current issue of Cell (Guettler et al., 2011; Levaot et al., 2011) highlight cherubism as an intriguing example. Cherubism is a dominantly inherited syndrome characterized by progressive loss of bone in the jaws and accumulation of inflammatory/fibrous tissue in the lower face. These studies provide molecular insight into the etiology of this disease, revealing a role for the poly(ADP-ribose) polymerase Tankyrase in normal bone homeostasis and providing important inroads toward the understanding of Tankyrase functions.
A breakthrough in understanding the cause of cherubism was the identification of mutations in the SH3-binding protein SH3BP2 (Cicchetti et al., 1992) in several cherubism families (Ueki et al., 2001) . Curiously, all mutations were missense mutations within a hexapeptide sequence, RSPPDG, located between the N-terminal pleckstrin homology domain and C-terminal SH2 domain of SH3BP2 (see Figure 1) . Genetic considerations suggested that the mutations were unlikely to represent loss-of-function mutations (Ueki et al., 2001) , and Ueki et al. (2007) found that homozygous mutants carrying the most common mutation, a proline-to-arginine substitution (P418R in humans; P416R in mice) knocked into the mouse Sh3bp2 gene, exhibited major hallmarks of cherubism after birth: bone loss, enhanced osteoclast differentiation, and systemic inflammation. The SH3BP2 mutation caused enhanced ERK1/2-mediated TNF-a expression in macrophages and increased levels of SYK activation in osteoclasts in vitro. Overexpression of wild-type SH3BP2 had the same effects, indicating that cherubism mutations represent gain of SH3BP2 function. TNF-a appeared crucial for the homozygous phenotype as its absence resulted in rescue of inflammation and a major portion of the bone loss. Finally, bone marrow transplantation experiments provided evidence that cherubism, despite its jaw-restricted phenotype in humans, is primarily a disorder of myeloid cells.
These studies provided significant insights into the pathogenesis of cherubism, but important questions were left unanswered, including the question of how sequence changes within the RSPPDG motif increase SH3BP2 function. In this issue of Cell, Levaot et al. (2011) and Guettler et al. (2011) provide the answer: Cherubism mutations abolish recognition of SH3BP2 by Tankyrase (TNKS/ TNKS2) (Hsiao and Smith, 2008; Smith et al., 1998) , resulting in increased stability and levels of SH3BP2 and hyperactivation of SRC, SYK, and VAV pathways. Levaot et al. (2011) show that SH3BP2 binds to TNKS2 via the RSPPDG motif; TNKS2-mediated PARsylation of SH3BP2 targets it for ubiquitylation by the E3-ubiquitin ligase RNF146 and subsequent degradation. Levaot et al. (2011) found that monocytes isolated from Tnks2-deficient mice showed rates of osteoclast formation that were intermediate between rates obtained with control and homozygous cherubism macrophages. Furthermore, monocytes depleted for both TNKS and TNKS2 or RNF146 showed enhanced osteoclast formation, high levels of SRC, SYK, and VAV phosphorylation, and increased levels of SH3BP2, similar to the osteoclast phenotype in cells harboring the homozygous P416R cherubism mutation in SH3BP2. Poly(ADP-ribose) polymerase (PARP) inhibitors enhanced osteoclastogenesis in an SH3BP2-dependent manner, and wild-type macrophages treated with PARP inhibitor showed increased levels of TNF-a secretion compared with control cells, similar to macrophages harboring the P416R cherubism mutation. Hyperactivation of osteoclasts mediated by stabilized SH3BP2 could be completely antagonized by inhibition of SRC. Combined with the finding that lack of TNF-a in homozygous cherubism mice results in rescue of the inflammatory and major bone loss phenotypes (Ueki et al., 2007) , the data suggest that a combination of anti-TNF-a antibody and SRC inhibitors may be effective in the treatment of cherubism.
Elegant and definitive structural evidence that dysregulation of substrate recognition by Tankyrase is indeed the underlying mechanistic basis of cherubism is provided by Guettler et al. (2011) . The authors also use the cherubism case study as a starting point for defining general sequence rules guiding recognition of all potential substrates by TNKS/ TNKS2. Using a peptide from the Tankyrase-binding region of SH3BP2 in binding assays with the entire ankyrin repeat region or individual ankyrin repeat clusters (ARCs), the authors confirm that there are at least four functional substratebinding sites in TNKS2 (Seimiya et al., 2004) . Any of the five ARCs, except ARC3, binds SH3BP2 control peptide but not SH3BP2 variants with the cherubism mutations R413Q or P416H. The crystal structure of the apo form and an SH3BP2 peptide-bound form of ARC4 indicates that an ARC contains a stack of five ankyrin repeats, with the SH3BP2 motif RSPPDGQS binding to a pocket formed by the central three ankyrin repeats. Remarkably, crystal structures of ARC4 bound to recognition peptides from additional Tankyrase substrates revealed that all substrates employ a common binding mode despite the variability of the interaction sequence. To obtain further insight into ARC binding to different substrate sequences, the authors used the SH3BP2 peptide RSPPDGQS to construct a peptide library with each position in the sequence exchanged with each of the 20 standard amino acid residues. Testing the peptides in binding assays with ARC4, the authors show that arginine and glycine in positions 1 and 6 are critical for binding, and that all characterized cherubism mutations (Lietman et al., 2006; Ueki et al., 2001) act by abolishing binding of the SH3BP2 motif to ARCs. Finally, the use of substrate recognition rules to predict, based on an in silico search of the human proteome, potential Tankyrase interactors leads to the conclusion that a wide range, possibly hundreds, of proteins may be Tankyrase substrates, thus raising the possibility that Tankyrase-dependent regulation of cellular activities may be more widespread than currently recognized.
The two studies highlighted here reveal the mechanism by which Tankyrase regulates SH3BP2 stability and how mutations in cherubism, like a perfect mutagenesis experiment of nature, disrupt this regulation. However, this does not mean that all questions associated with cherubism have been answered. For example, it remains unclear how the SH3BP2 mutations cause defects that are primarily restricted to the jaws in humans, or why the phenotype regresses after puberty. Is it possible that Tankyrase-independent mechanisms that control SH3BP2 levels or activity are less active in the jaws than in other regions of the human skeleton? Could such mechanisms become more efficient after puberty? Are the mechanisms by which SH3BP2 controls osteoclast formation and TNF-a levels in macrophages positively modulated by processes that are more active in the growing human jaws than in other organs? Given what we now know about cherubism, it should be possible to design systematic studies to answer these and other questions. Schematic representation of the domain structures of SH3BP2 (pleckstrin homology [PH] and SH2 domains) and Tankyrase 2 (TNKS2) (five ankyrin repeat clusters-ARCs, a sterile-alpha motif-SAM, and a PARP catalytic domain) and their interaction via the substrate recognition sequence RSPPDG in SH3BP2 (at left). Although RSPPDGQS was the sequence utilized by Guettler et al. (2011) for binding, only the shorter sequence, RSPPDG, is shown in the figure because Levaot et al. (2011) demonstrated that it was sufficient for binding. In Tankyrase, ARCs 1, 2, 4, and 5 can bind substrate recognition sequences. For simplicity and because ARC4 was used for crystal structure analyses by Guettler et al. (2011) , SH3BP2 is shown as interacting with ARC4. In contrast to the Tankyrase-mediated PARsylation of wild-type SH3BP2, followed by RNF146-dependent ubiquitylation and proteosomal degradation, SH3BP2 with a cherubism mutation, such as P416R (at right), does not bind to Tankyrase. As a consequence, mutant SH3BP2 accumulates, downstream targets are hyperactivated, and osteoclast formation and TNF-a production are increased.
